Free Trial
NASDAQ:IMA

ImageneBio Q4 2023 Earnings Report

ImageneBio logo
$8.15 +0.45 (+5.84%)
As of 04:00 PM Eastern

ImageneBio EPS Results

Actual EPS
-$4.92
Consensus EPS
-$4.92
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

ImageneBio Revenue Results

Actual Revenue
$0.66 million
Expected Revenue
$2.39 million
Beat/Miss
Missed by -$1.73 million
YoY Revenue Growth
N/A

ImageneBio Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Tuesday, March 12, 2024
Conference Call Time
3:00AM ET

ImageneBio Earnings Headlines

ImageneBio (IMA) & Its Competitors Head to Head Review
Wall Street Zen Upgrades ImageneBio (NASDAQ:IMA) to Hold
Is Nvidia about to Trigger Another 150X Opportunity?
Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics processing units. Legendary investor Louis Navellier believes this new invention could be even more revolutionary and mint a new wave of millionaires.tc pixel
See More ImageneBio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ImageneBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImageneBio and other key companies, straight to your email.

About ImageneBio

ImageneBio (NASDAQ:IMA), a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

View ImageneBio Profile

More Earnings Resources from MarketBeat